Intersect ENT, Inc. (NASDAQ:XENT) Ratings Summary as of Apr 17, 2018

April 17, 2018 - By Russell Jones

Intersect ENT, Inc. (NASDAQ:XENT) Corporate Logo

Intersect ENT, Inc. (NASDAQ:XENT) Ratings Coverage

In total 3 analysts cover Intersect ENT (NASDAQ:XENT). “Buy” rating has 2, “Sell” are 0, while 1 are “Hold”. 67% are bullish. 4 are the (NASDAQ:XENT)’s analyst reports since November 6, 2017 according to StockzIntelligence Inc. On Wednesday, December 6 the firm has “Buy” rating given by Canaccord Genuity. On Thursday, January 4 the rating was maintained by Canaccord Genuity with “Buy”. In Tuesday, January 2 report JP Morgan upgraded the stock to “Overweight” rating. Listed here are Intersect ENT, Inc. (NASDAQ:XENT) PTs and latest ratings.

04/01/2018 Broker: Canaccord Genuity Rating: Buy New Target: $43.0 Maintain
02/01/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Overweight Upgrade
06/12/2017 Broker: Canaccord Genuity Rating: Buy New Target: $36.0 Maintain
06/11/2017 Broker: BTIG Research Rating: Hold

On during the last trading session the stock increased $1.25 or 3.16%, reaching $40.8.Intersect ENT, Inc. has volume of 227,774 shares. Since April 17, 2017 XENT has risen 124.86% and is uptrending. XENT outperformed by 113.31% the S&P 500.

Intersect ENT, Inc., a commercial stage drug-device company, provides therapeutic solutions for patients with ear, nose, and throat conditions in the United States.The firm is worth $1.22 billion. It offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses.Last it reported negative earnings. The firm is also developing RESOLVE, a steroid releasing implant for refractory disease for the treatment of patients in the physician office setting.

Intersect ENT, Inc. (NASDAQ:XENT) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: